Our goal is to close the gap between antibody discovery and therapeutic antibody development by developing next generation therapeutic antibodies. We have established unique platforms for antibody development that apply a combination of computer-aided design and traditional antibody discovery technologies. We believe in a “quality by design” concept and work to create novel therapeutic antibodies that can target difficult-to-treat cancers and CNS diseases.
